Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Licensing Models For New Markets - BIO Conference

This article was originally published in PharmAsia News

Executive Summary

CHICAGO - Whether or not the world is flat, licensing deals are no longer simply a transfer of global rights, and pharma companies are trying to determine how best to carve up regional rights and how to coordinate marketing efforts

You may also be interested in...

Kyowa Hakko Kirin, Ultragenyx To Develop Treatment For X-linked Hypophosphatemia

Kyowa Hakko Kirin is committed to expansion, and the deal with Ultragenyx for a first-in-class therapy of a rare bone disorder is small but establishes a clinical trial foothold overseas

Japanese Products Can Find A Home In Emerging Markets With Partners Like Roche

Roche plans to sign China-exclusive in-licensing deals with two Japanese pharma by the end of the year. The head-start of Roche and other western pharma has given them the capability and appetite for larger portfolios in key Asian markets.

Japanese Pharma, Hungry For Global Deals, Can Fill Gap of Shrinking Partners - PharmAsia Summit

SAN FRANCISCO - The number of large Western pharmaceutical companies is shrinking due to M&A activity, and outward-looking Japanese firms of all sizes are quickly becoming an attractive option for biotechs looking for global and regional deals

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts